Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470710 | 1.00 | IDO1 (0.46) | IDO1TDO2GBA1HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL28716274 | 0.98 | IDO1 (0.49) | IDO1TDO2GBA1HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL29487201 | 0.98 | IDO1 (0.49) | IDO1TDO2GBA1HTR2ATAAR1 | |
| SCHEMBL30689582 | 0.86 | TAAR1 (0.47) | IDO1TDO2GBA1HTR2ATAAR1 | |
| SCHEMBL3542231 | 0.84 | TAAR1 (0.46) | HTR2ATAAR1ANPEPENPEP | |
| SCHEMBL25370972 | 0.82 | GBA1 (0.47) | IDO1TDO2GBA1TAAR1MAOA | |
| SCHEMBL8515046 | 0.82 | GBA1 (0.47) | IDO1TDO2GBA1TAAR1MAOA | |
| SCHEMBL1459476 | 0.82 | GBA1 (0.47) | IDO1TDO2GBA1TAAR1MAOA | |
| SCHEMBL12479861 | 0.82 | GBA1 (0.47) | IDO1TDO2GBA1TAAR1MAOA | |
| SCHEMBL16396890 | 0.82 | GBA1 (0.47) | IDO1TDO2GBA1TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | IDO1 4504/4885TDO2 4651/4885GBA1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.